AC Immune (ACIU) Return on Invested Capital (2022 - 2023)
AC Immune's (ACIU) quarterly Return on Invested Capital came in at 0.04% in Q4 2023, little changed year-on-year from 0.04% in Q4 2022, and up 32.23% on a QoQ basis from 0.05% in Q3 2023.
AC Immune (ACIU) Return on Invested Capital (2022 - 2023) Analysis & Trends
AC Immune (ACIU) has 2 years of Return on Invested Capital data on file, last reported at 0.04% in Q4 2023.
- On a quarterly basis, Return on Invested Capital changed 0.0% year-over-year to 0.04% in Q4 2023; TTM through Dec 2023 was 0.04%, a 0.0% change from a year earlier, with the FY2024 full-year figure at 0.03%, up 1.0% from the prior year.
- Return on Invested Capital for Q4 2023 stood at 0.04%, up from 0.05% in the prior quarter.
- Over the last five years, Return on Invested Capital for ACIU reached as high as 0.03% in Q3 2022 and fell as low as 0.05% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.04% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | AC Immune | 225.68 Mn | 225.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -0.04% |
| Sep 30, 2023 | -0.05% |
| Jun 30, 2023 | -0.05% |
| Mar 31, 2023 | -0.05% |
| Dec 31, 2022 | -0.04% |
| Sep 30, 2022 | -0.03% |
| Jun 30, 2022 | -0.04% |
| Mar 31, 2022 | -0.04% |